Total and free serum concentrations of carbamazepine and carbamazepine-10,11-epoxide in children with epilepsy. 1986

O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles

Simultaneous steady-state serum total and free (non-protein-bound) concentrations of carbamazepine and carbamazepine-10,11-epoxide were measured in 68 patients under the age of 21 years with epilepsy (44 males, 24 females; mean age, 11.8 +/- 4.5 years). Thirty patients were maintained on monotherapy with carbamazepine. Mean serum total carbamazepine and carbamazepine-10,11-epoxide concentrations obtained were 7.0 +/- 2.4 mg/L (29.5 +/- 10.0 mumol/L) and 1.5 +/- 0.6 mg/L (5.9 +/- 2.6 mumol/L), respectively. Mean serum-free carbamazepine and carbamazepine-10,11-epoxide concentrations obtained were 1.3 +/- 0.5 mg/L (5.7 +/- 2.1 mumol/L) and 0.5 +/- 0.3 mg/L (2.2 +/- 1.1 mumol/L), respectively. Binding of carbamazepine and carbamazepine-10,11-epoxide was 81% +/- 3% and 62% +/- 10%, respectively. There was no significant difference in binding between male and female patients or those maintained on monotherapy and polytherapy. Age correlated significantly with carbamazepine binding but not with carbamazepine-10,11-epoxide binding. Free concentrations of carbamazepine and carbamazepine-10,11-epoxide correlated significantly with total carbamazepine and total carbamazepine-10,11-epoxide concentrations, respectively, indicating that the binding capacities of both carbamazepine and carbamazepine-10,11-epoxide are constant at serum total carbamazepine concentrations within the quoted therapeutic range.

UI MeSH Term Description Entries
D008297 Male Males
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles
March 1985, The Journal of pediatrics,
O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles
January 1985, Epilepsia,
O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles
January 1987, Pediatric neurology,
O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles
January 1977, European journal of clinical pharmacology,
O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles
December 1984, British journal of clinical pharmacology,
O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles
January 1989, Epilepsy research,
O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles
August 1978, Acta neurologica Scandinavica,
O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles
January 1985, European journal of clinical pharmacology,
O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles
January 1984, Therapeutic drug monitoring,
O A Agbato, and A A Elyas, and P N Patsalos, and E M Brett, and P T Lascelles
August 1976, British journal of clinical pharmacology,
Copied contents to your clipboard!